1. Introduction {#sec1-cancers-11-00970}
===============

MicroRNAs (miRNAs) are a wide family of small non-coding RNAs that have emerged as key players in regulating the expression of target genes and are therefore important in many biological processes \[[@B1-cancers-11-00970]\]. In the last two decades, a wealth of evidence has clarified the mechanisms through which miRNAs can modulate specific genes, increasing our knowledge on the fine-tuning regulation of protein expression \[[@B1-cancers-11-00970],[@B2-cancers-11-00970],[@B3-cancers-11-00970],[@B4-cancers-11-00970]\]. miRNAs have been shown to be involved in complex regulatory networks, basically playing a role in every aspect of the biology of cells and organs \[[@B5-cancers-11-00970],[@B6-cancers-11-00970]\]. Therefore, it is clear that miRNA deregulation may promote the disruption of a fine-tuned equilibrium within a cell, altering physiologically relevant functions \[[@B7-cancers-11-00970],[@B8-cancers-11-00970],[@B9-cancers-11-00970]\]. Consequently, it is not surprising that miRNA expression has been found to be dysregulated in the majority of human diseases, including cancer \[[@B10-cancers-11-00970],[@B11-cancers-11-00970]\]. miRNA deregulation takes place via different mechanisms such as (i) deletion or amplification of miRNA genes \[[@B12-cancers-11-00970],[@B13-cancers-11-00970]\]; (ii) aberrant expression of transcription factors \[[@B14-cancers-11-00970]\]; (iii) dysregulation of the miRNA biogenesis process \[[@B15-cancers-11-00970]\]; and (iv) miRNA sequestration (miRNA sponging) \[[@B16-cancers-11-00970],[@B17-cancers-11-00970],[@B18-cancers-11-00970]\]. miRNA deregulation can affect the hallmarks of cancer, including sustaining proliferation, evading apoptosis and resisting cell death, promoting invasion and metastasis, and inducing angiogenesis \[[@B19-cancers-11-00970]\]. In particular, miRNAs may act as oncogenes, tumor suppressors, or, depending on the cellular context, may have both functions \[[@B20-cancers-11-00970]\]. In addition to the cancerogenetic process, compelling evidence has shown that miRNAs can be involved in tumor sensitivity to treatment, showing a correlation with patients' clinical outcomes \[[@B21-cancers-11-00970],[@B22-cancers-11-00970],[@B23-cancers-11-00970],[@B24-cancers-11-00970]\].

miR-221 and miR-222 have been frequently identified as deregulated across different cancer types \[[@B25-cancers-11-00970],[@B26-cancers-11-00970],[@B27-cancers-11-00970],[@B28-cancers-11-00970],[@B29-cancers-11-00970],[@B30-cancers-11-00970]\]. These two miRNAs, encoded on chromosome X (Xp11.3), are highly homologous, share seed sequences, and usually act as a cluster (miR-221/222) \[[@B31-cancers-11-00970],[@B32-cancers-11-00970]\]. In particular, this cluster might promote the overcoming of the status of cell quiescence and increase proliferation, survival, and metastatic potential, acting as an oncogene \[[@B31-cancers-11-00970],[@B33-cancers-11-00970],[@B34-cancers-11-00970]\]. In addition, it is well documented that miR-221 and miR-222 play a key role in modulating the clinical outcome in cancer patients in both solid and hematological malignancies \[[@B30-cancers-11-00970],[@B35-cancers-11-00970]\]. In this regard, the prognostic value of miR-221 and miR-222 expression in cancer has been extensively investigated in the last decade, with controversial results. A number of studies support the hypothesis that their overexpression may be predictive for poor cancer survival \[[@B36-cancers-11-00970],[@B37-cancers-11-00970]\], while others reported a better prognosis \[[@B38-cancers-11-00970],[@B39-cancers-11-00970]\] or failed to find a significant association \[[@B40-cancers-11-00970],[@B41-cancers-11-00970]\]. Few meta-analyses have investigated the association between miR-221/222 \[[@B42-cancers-11-00970],[@B43-cancers-11-00970],[@B44-cancers-11-00970]\] and malignancies; however, their prognostic role in cancer patients has not been fully analyzed. In addition, single studies may be underpowered to achieve a comprehensive and reliable conclusion. Given these premises, it is imperative and timely to perform an exhaustive meta-analysis to evaluate the prognostic value of miR-221/222 expression in cancer patients. Therefore, we systematically performed a meta-analysis based on all eligible studies to evaluate the association between miR-221/222 expression and the prognosis of patients with malignant tumors.

2. Methods {#sec2-cancers-11-00970}
==========

2.1. Search Strategy {#sec2dot1-cancers-11-00970}
--------------------

The present systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement principles \[[@B45-cancers-11-00970]\]. The PubMed, Web of Knowledge, and Cochrane Library databases were systematically searched for original articles analyzing the prognostic value of miR-221/222 in different cancer patients (last updated search 28 September 2018). Relevant studies were selected using Boolean combinations of the following key terms variably combined: "miR-221 OR miR-222 OR miRNA-221 OR miRNA-222" OR miR-221/222 AND "cancer OR tumor OR tumour OR neoplasia OR tumors OR tumours OR cancers" AND "survival OR prognosis OR progression". Additionally, the reference list of review papers, meta-analyses, and all original studies were hand searched to acquire further relevant studies missed by the initial electronic quest.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-cancers-11-00970}
-------------------------------------

Eligible studies were required to meet the following inclusion criteria: (i) miR-221/222 expression measured in the tumor tissue; (ii) investigating the correlation of miR-221 or miR-222 expression level with human cancer prognosis; and (iii) reporting hazard ratios (HR) with corresponding 95% confidence intervals (CI) or sufficient information to estimate them. Exclusion criteria were (i) circulating miRNA, case reports, review articles, and editorials; (ii) non-human and in vitro studies; and (iii) non-English articles. When more than one study had been published sharing part of the same patient population, only the most recent and complete study was selected in this meta-analysis.

2.3. Data Extraction {#sec2dot3-cancers-11-00970}
--------------------

After removing duplicated studies, two independent investigators (G.S. and F.Z.) carefully read the titles and abstracts of the relevant articles and judged their eligibility. Then, the entire text of potential eligible studies was evaluated to assess appropriateness for inclusion in the meta-analysis. Disagreements were resolved by discussion with another investigator (S.T. or S.A.) for consensus. Two authors (G.R. and S.C.) independently extracted the data from all included studies. The following data were sought and recorded: (1) first author, publication year, and nationality of studied population; (2) miRNA analyzed, cancer type, sample type, and miRNA assay method; and (3) sample size, cut-off value, HR, and corresponding 95% CI. When a study reported the survival results of both univariate and multivariate analyses, only the latter was extracted, as it accounts for confounding factors and is therefore more accurate. For studies only providing Kaplan--Meier curves, variables were read from the graphical survival plots using PlotDigitizer software (version 2.6.8, freely available at <http://plotdigitizer.sourceforge.net>); after that the HR value and 95% CI were estimated via the method described by Parmar et al. \[[@B46-cancers-11-00970]\]. Finally, extracted data were crosschecked by two investigators (G.R. and S.C.), and any divergences were resolved by discussion with a third author (S.T. or S.A.).

2.4. Outcomes and Definition {#sec2dot4-cancers-11-00970}
----------------------------

In the present study, all survival outcomes were extracted. Overall survival (OS) was the primary outcome of interest selected to calculate the association with miR-221 and/or miR-222 expression in cancer patients. OS was defined as the length of time from when the sample was obtained to the date of death from any cause or the date of last follow-up. All the others were considered secondary survival outcomes.

2.5. Quality Assessment {#sec2dot5-cancers-11-00970}
-----------------------

The scientific quality of the included studies was evaluated according to the Newcastle--Ottawa Scale (NOS) for nonrandomized studies \[[@B47-cancers-11-00970]\]. The methodological quality of included studies was firstly evaluated by two investigators (G.S. and F.Z.) and then by two other investigators (G.R and S.C.) in a second round of study quality evaluation; any disagreement was resolved through consensus. The NOS, assigning up to a maximum of 9 points, consists of three components: (I) selection and definition of the study groups (0--4 points); (II) comparability of the cohorts (0--2 points); and (III) ascertainment of outcomes (0--3 points). A possible score of 0--9 was assigned to each study. Studies with a NOS score greater than 7 were considered of high quality.

2.6. Statistical Analysis {#sec2dot6-cancers-11-00970}
-------------------------

Analyses were performed using ProMeta software Version 2 (INTERNOVI di Scarpellini Daniele s.a.s., Cesena FC, Italy). The pooled HR and corresponding 95% CI were used to evaluate the prognostic value of miR-221 and/or miR-222 for different malignancies. All analyses were performed using the low miR-221/222 expression group as the reference group (HR = 1). An observed HR of \>1 implies a worse prognosis for the group with higher miR-221/222 expression. Heterogeneity between studies was estimated using the χ^2^-based Cochran's Q statistic (significant for *p* \< 0.10) \[[@B48-cancers-11-00970]\], and the *I*^2^ index (range 0%--100%) which quantifies heterogeneity irrespective of the number of studies (an *I*^2^ of over 50% is interpreted as the presence of large degree of heterogeneity) \[[@B49-cancers-11-00970]\]. Survival outcomes were pooled using the random effects model which takes into account both within-study variance and between-study variance; the random effects model coincides with the fixed effect model in the absence of heterogeneity (*I*^2^ = 0) \[[@B34-cancers-11-00970]\]. To assess the robustness of the overall findings, subgroup analyses were conducted based on multiple criteria, including patient ethnicity, tumor type, biological specimen, sample size, survival analysis, and NOS. Additionally, the presence of small-study effects and publication bias was evaluated graphically by funnel plots and statistically by means of Egger's test \[[@B50-cancers-11-00970]\]. An Egger's test *p* value of \<0.10 was considered statistically significant. Moreover, leave-one-out meta-analysis was performed to identify studies that had a crucial influence on the pooled HR by removing one study at a time.

3. Results {#sec3-cancers-11-00970}
==========

3.1. Study Characteristics and Quality Assessment {#sec3dot1-cancers-11-00970}
-------------------------------------------------

The study selection process on the PubMed, Web of Knowledge, and Cochrane databases yielded 852 studies. After removing 242 duplicated publications, the remaining 610 records were evaluated by carefully reading titles and abstracts, after which 248 studies were excluded for the following reasons: only in vitro studies, reviews or meta-analyses, non-human studies, not in English, and case reports. Then, the entire text of the remaining 362 studies was assessed, determining the removal of 312 further studies. Finally, 50 articles, published between 2009 and 2018, were included in the systematic review \[[@B35-cancers-11-00970],[@B36-cancers-11-00970],[@B37-cancers-11-00970],[@B38-cancers-11-00970],[@B39-cancers-11-00970],[@B40-cancers-11-00970],[@B41-cancers-11-00970],[@B51-cancers-11-00970],[@B52-cancers-11-00970],[@B53-cancers-11-00970],[@B54-cancers-11-00970],[@B55-cancers-11-00970],[@B56-cancers-11-00970],[@B57-cancers-11-00970],[@B58-cancers-11-00970],[@B59-cancers-11-00970],[@B60-cancers-11-00970],[@B61-cancers-11-00970],[@B62-cancers-11-00970],[@B63-cancers-11-00970],[@B64-cancers-11-00970],[@B65-cancers-11-00970],[@B66-cancers-11-00970],[@B67-cancers-11-00970],[@B68-cancers-11-00970],[@B69-cancers-11-00970],[@B70-cancers-11-00970],[@B71-cancers-11-00970],[@B72-cancers-11-00970],[@B73-cancers-11-00970],[@B74-cancers-11-00970],[@B75-cancers-11-00970],[@B76-cancers-11-00970],[@B77-cancers-11-00970],[@B78-cancers-11-00970],[@B79-cancers-11-00970],[@B80-cancers-11-00970],[@B81-cancers-11-00970],[@B82-cancers-11-00970],[@B83-cancers-11-00970],[@B84-cancers-11-00970],[@B85-cancers-11-00970],[@B86-cancers-11-00970],[@B87-cancers-11-00970],[@B88-cancers-11-00970],[@B89-cancers-11-00970],[@B90-cancers-11-00970],[@B91-cancers-11-00970],[@B92-cancers-11-00970],[@B93-cancers-11-00970]\]. A detailed flow-chart illustrating the literature selection process is presented in [Figure 1](#cancers-11-00970-f001){ref-type="fig"}.

The main general information on the included studies are reported in [Table 1](#cancers-11-00970-t001){ref-type="table"} and [Table 2](#cancers-11-00970-t002){ref-type="table"}. Among them, 27 focused on miR-221 \[[@B36-cancers-11-00970],[@B38-cancers-11-00970],[@B40-cancers-11-00970],[@B52-cancers-11-00970],[@B54-cancers-11-00970],[@B57-cancers-11-00970],[@B60-cancers-11-00970],[@B61-cancers-11-00970],[@B62-cancers-11-00970],[@B64-cancers-11-00970],[@B69-cancers-11-00970],[@B70-cancers-11-00970],[@B72-cancers-11-00970],[@B73-cancers-11-00970],[@B74-cancers-11-00970],[@B75-cancers-11-00970],[@B79-cancers-11-00970],[@B80-cancers-11-00970],[@B81-cancers-11-00970],[@B82-cancers-11-00970],[@B83-cancers-11-00970],[@B84-cancers-11-00970],[@B85-cancers-11-00970],[@B88-cancers-11-00970],[@B89-cancers-11-00970],[@B91-cancers-11-00970],[@B92-cancers-11-00970]\], 11 on miR-222 \[[@B37-cancers-11-00970],[@B39-cancers-11-00970],[@B53-cancers-11-00970],[@B56-cancers-11-00970],[@B59-cancers-11-00970],[@B63-cancers-11-00970],[@B67-cancers-11-00970],[@B68-cancers-11-00970],[@B86-cancers-11-00970],[@B87-cancers-11-00970],[@B93-cancers-11-00970]\], and the remaining 12 investigated the cluster miR-221/miR-222 \[[@B35-cancers-11-00970],[@B41-cancers-11-00970],[@B51-cancers-11-00970],[@B55-cancers-11-00970],[@B58-cancers-11-00970],[@B65-cancers-11-00970],[@B66-cancers-11-00970],[@B71-cancers-11-00970],[@B76-cancers-11-00970],[@B77-cancers-11-00970],[@B78-cancers-11-00970],[@B90-cancers-11-00970]\]. Overall, 6086 patients suffering from different tumors were included in the systematic review, with the sample size in each study ranging from 20 to 393 patients. With regard to the cancer type, three studies focused on hematological tumors \[[@B56-cancers-11-00970],[@B62-cancers-11-00970],[@B92-cancers-11-00970]\], whereas all the others evaluated solid tumors. Overall, the most evaluated neoplasms in the present meta-analysis were hepatocellular carcinoma (HCC; 7 studies) \[[@B54-cancers-11-00970],[@B64-cancers-11-00970],[@B71-cancers-11-00970],[@B80-cancers-11-00970],[@B83-cancers-11-00970],[@B91-cancers-11-00970],[@B93-cancers-11-00970]\], non-small cell lung cancer (NSCLC; 5 studies) \[[@B37-cancers-11-00970],[@B67-cancers-11-00970],[@B79-cancers-11-00970],[@B84-cancers-11-00970],[@B86-cancers-11-00970]\], prostate cancer (PCa; 5 studies) \[[@B51-cancers-11-00970],[@B52-cancers-11-00970],[@B60-cancers-11-00970],[@B66-cancers-11-00970],[@B76-cancers-11-00970]\], breast cancer (BC; 4 studies) \[[@B61-cancers-11-00970],[@B75-cancers-11-00970],[@B81-cancers-11-00970],[@B87-cancers-11-00970]\], and colorectal cancer (CRC; 4 studies) \[[@B38-cancers-11-00970],[@B40-cancers-11-00970],[@B72-cancers-11-00970],[@B90-cancers-11-00970]\]. The majority of the studies were performed in Asia (32/50, 64%; 25 in China) and Europe (10/50, 20%). All the studies were retrospective in design; qRT-PCR was mostly used to measure the expression of miR-221/222 (45/50 studies, 90%). Twenty-four out of 50 studies (48%) measured the expression in formalin-fixed, paraffin-embedded (FFPE) samples, 21 (42%) in fresh/frozen tissue, 2 studies used both specimens, another 2 studies (4%) did not specifically report the tissue type, and 1 used bone marrow. The cut-off value stratifying patients into high and low expression groups varied among the different studies, with the median value being the most broadly used value (26/50 studies, 52%). The length of follow-up ranged from 24 to 300 months. Regarding the quality of included studies, the NOS scores ranged from 5 to 9 (median 7). Thirty-six studies that had scores of ≥7 were categorized as high-quality studies \[[@B35-cancers-11-00970],[@B36-cancers-11-00970],[@B37-cancers-11-00970],[@B38-cancers-11-00970],[@B39-cancers-11-00970],[@B40-cancers-11-00970],[@B41-cancers-11-00970],[@B51-cancers-11-00970],[@B52-cancers-11-00970],[@B54-cancers-11-00970],[@B56-cancers-11-00970],[@B57-cancers-11-00970],[@B59-cancers-11-00970],[@B60-cancers-11-00970],[@B61-cancers-11-00970],[@B62-cancers-11-00970],[@B65-cancers-11-00970],[@B66-cancers-11-00970],[@B67-cancers-11-00970],[@B68-cancers-11-00970],[@B69-cancers-11-00970],[@B70-cancers-11-00970],[@B71-cancers-11-00970],[@B72-cancers-11-00970],[@B73-cancers-11-00970],[@B75-cancers-11-00970],[@B77-cancers-11-00970],[@B78-cancers-11-00970],[@B79-cancers-11-00970],[@B80-cancers-11-00970],[@B84-cancers-11-00970],[@B85-cancers-11-00970],[@B87-cancers-11-00970],[@B89-cancers-11-00970],[@B90-cancers-11-00970],[@B92-cancers-11-00970]\], while the remaining 14, which had scores of \<7, were categorized as low-quality studies \[[@B53-cancers-11-00970],[@B55-cancers-11-00970],[@B58-cancers-11-00970],[@B63-cancers-11-00970],[@B64-cancers-11-00970],[@B74-cancers-11-00970],[@B76-cancers-11-00970],[@B81-cancers-11-00970],[@B82-cancers-11-00970],[@B83-cancers-11-00970],[@B86-cancers-11-00970],[@B88-cancers-11-00970],[@B91-cancers-11-00970],[@B93-cancers-11-00970]\].

3.2. Impact of miR-221 Expression on Survival Outcomes {#sec3dot2-cancers-11-00970}
------------------------------------------------------

With regard to miR-221, 25 \[[@B35-cancers-11-00970],[@B36-cancers-11-00970],[@B38-cancers-11-00970],[@B40-cancers-11-00970],[@B41-cancers-11-00970],[@B55-cancers-11-00970],[@B57-cancers-11-00970],[@B58-cancers-11-00970],[@B62-cancers-11-00970],[@B64-cancers-11-00970],[@B69-cancers-11-00970],[@B71-cancers-11-00970],[@B72-cancers-11-00970],[@B73-cancers-11-00970],[@B78-cancers-11-00970],[@B79-cancers-11-00970],[@B80-cancers-11-00970],[@B82-cancers-11-00970],[@B83-cancers-11-00970],[@B84-cancers-11-00970],[@B85-cancers-11-00970],[@B88-cancers-11-00970],[@B89-cancers-11-00970],[@B90-cancers-11-00970],[@B92-cancers-11-00970]\] out of the 50 studies included in the systematic review evaluated the relationship between miR-221 expression and OS in patients suffering from different tumors. Three studies reported cancer-specific survival (CSS) \[[@B61-cancers-11-00970],[@B70-cancers-11-00970],[@B91-cancers-11-00970]\] and one reported the disease-specific survival (DSS) \[[@B77-cancers-11-00970]\]. Concerning secondary outcomes, six studies reported disease-free survival (DFS) \[[@B35-cancers-11-00970],[@B38-cancers-11-00970],[@B62-cancers-11-00970],[@B74-cancers-11-00970],[@B80-cancers-11-00970],[@B81-cancers-11-00970]\]; five reported recurrence-free survival (RFS) \[[@B51-cancers-11-00970],[@B52-cancers-11-00970],[@B60-cancers-11-00970],[@B66-cancers-11-00970],[@B75-cancers-11-00970]\]; four reported progression-free survival (PFS) \[[@B35-cancers-11-00970],[@B71-cancers-11-00970],[@B76-cancers-11-00970],[@B77-cancers-11-00970]\]; one reported the distant metastasis rate (DMR) and local recurrence rate (LRR) \[[@B40-cancers-11-00970]\]; and three studies reported the time to local recurrence (TTLR) \[[@B54-cancers-11-00970]\], time to recurrence (TTR) \[[@B91-cancers-11-00970]\], and metastasis-free survival (MFS) \[[@B65-cancers-11-00970]\], respectively.

### 3.2.1. miR-221 Expression and OS {#sec3dot2dot1-cancers-11-00970}

We observed a high degree of heterogeneity among the 25 studies reporting OS and included in the meta-analysis (*I*^2^ = 75%, *p* \< 0.001). Despite this, the pooled HR indicated a significantly short OS in patients with higher expression of miR-221 (N~patients~ = 2240; HR: 1.48, 95% CI: 1.14--1.93, *p* = 0.003; [Figure 2](#cancers-11-00970-f002){ref-type="fig"}A). No evidence of publication bias or small-study effects was observed in either the funnel plot ([Figure 2](#cancers-11-00970-f002){ref-type="fig"}B) or in Egger's test (*p* = 0.770).

In order to assess the robustness of the overall finding, subgroup analyses were further performed based on seven subcategories: ethnicity, tumor type, pre-operative treatment, specimen, sample size, survival analysis (univariate or multivariate), and NOS score ([Table 3](#cancers-11-00970-t003){ref-type="table"}). Statistically significant heterogeneity was detected in all the subgroup analyses except for studies performed in patients with liver cancer (*I*^2^ = 0%, *p* = 0.698) or NSCLC (*I*^2^ = 0%, *p* = 0.602) or with no pre-operative anticancer treatment (*I*^2^ = 0%, *p* = 0.813). When stratified by ethnicity, miR-221 overexpression was significantly correlated with poor OS in Asians with the combined HR being 1.67 (95% CI: 1.30--2.14, *p* \< 0.001). When stratified by cancer types, high miR-221 expression was associated with poor OS in patients with liver cancer (pooled HR: 1.98, 95% CI: 1.51--2.60, *p* \< 0.001) and NSCLC (pooled HR: 1.92, 95% CI: 1.31--2.81, *p* = 0.001). When stratified by pre-operative anticancer treatment, high miR-221 expression was associated with poor OS in patients with no pre-treatment (pooled HR: 1.84, 95% CI: 1.56--2.17, *p* \< 0.001). In the subgroup analysis stratified by type of biological specimen, high miR-221 expression showed a significant relationship with poor OS in both FFPE samples (pooled HR: 1.68, 95% CI: 1.20--2.36, *p* = 0.003) and fresh/frozen tissue (pooled HR: 1.54, 95% CI: 1.05--2.28, *p* = 0.028). For the subgroup analysis of sample size, high expression of miR-221 in samples of \<100 patients was significantly associated with poor OS (pooled HR: 1.62, 95% CI: 1.21--2.18, *p* \< 0.001), whereas no association was observed in samples of equal to or greater than 100 patients. The analysis also showed that high expression of miR-221 was significantly associated with poor OS in both the survival methods. Finally, in subgroup analysis stratified by quality assessment, high miR-221 expression was associated with poor OS in high-quality studies, with the combined HR being 1.61 (95% CI 1.20--2.16, *p* = 0.002).

The four studies reporting CSS \[[@B61-cancers-11-00970],[@B70-cancers-11-00970],[@B91-cancers-11-00970]\] and DSS \[[@B77-cancers-11-00970]\] available for the meta-analysis were characterized by significant heterogeneity (*I*^2^ = 88%, *p* \< 0.001). No significant association was found between CSS/DSS and high expression of miR-221, with the pooled HR being 0.95 (95% CI: 0.52--1.76, *p* = 0.878; [Table 4](#cancers-11-00970-t004){ref-type="table"}). The forest plot is shown in [Supplementary Figure S1](#app1-cancers-11-00970){ref-type="app"}. We also analyzed OS along with CSS and DSS. Despite significant heterogeneity (*I*^2^ = 77%; *p* \< 0.001), high miR-221 expression was significantly associated with poor OS/CSS/DSS (pooled HR: 1.38, 95% CI: 1.09--1.74, *p* = 0.007; [Supplementary Figure S2](#app1-cancers-11-00970){ref-type="app"}).

### 3.2.2. miR-221 Expression and Secondary Outcomes {#sec3dot2dot2-cancers-11-00970}

DFS was analyzed along with RFS by pooling together 11 studies \[[@B35-cancers-11-00970],[@B38-cancers-11-00970],[@B51-cancers-11-00970],[@B52-cancers-11-00970],[@B60-cancers-11-00970],[@B62-cancers-11-00970],[@B66-cancers-11-00970],[@B74-cancers-11-00970],[@B75-cancers-11-00970],[@B80-cancers-11-00970],[@B81-cancers-11-00970]\] encompassing 913 cancer patients. We observed a large degree of heterogeneity (*I*^2^ = 84%, *p* \< 0.001) and no significant association between disease progression and high expression of miR-221 (HR: 0.90, 95% CI: 0.46--1.75, *p* = 0.753; [Supplementary Figure S3A](#app1-cancers-11-00970){ref-type="app"}). No evidence of publication bias or small-study effects was observed in either the funnel plot ([Supplementary Figure S3B](#app1-cancers-11-00970){ref-type="app"}) or in Egger's test (*p* = 0.901). When assessing the association of miR-221 with PFS, no significant results were found ([Table 4](#cancers-11-00970-t004){ref-type="table"}).

3.3. Impact of miR-222 on Survival Outcomes {#sec3dot3-cancers-11-00970}
-------------------------------------------

Among the 23 studies focusing on the prognostic value of miR-222 in cancer patients, 17 studies investigated the effect of miR-222 overexpression on OS \[[@B35-cancers-11-00970],[@B37-cancers-11-00970],[@B39-cancers-11-00970],[@B41-cancers-11-00970],[@B53-cancers-11-00970],[@B55-cancers-11-00970],[@B58-cancers-11-00970],[@B59-cancers-11-00970],[@B63-cancers-11-00970],[@B65-cancers-11-00970],[@B67-cancers-11-00970],[@B68-cancers-11-00970],[@B71-cancers-11-00970],[@B78-cancers-11-00970],[@B86-cancers-11-00970],[@B90-cancers-11-00970],[@B93-cancers-11-00970]\]. Only one study reported DSS \[[@B77-cancers-11-00970]\] in place of OS. Concerning secondary outcomes, seven studies were available for the meta-analysis of miR-222 and PFS \[[@B35-cancers-11-00970],[@B55-cancers-11-00970],[@B56-cancers-11-00970],[@B71-cancers-11-00970],[@B76-cancers-11-00970],[@B77-cancers-11-00970],[@B86-cancers-11-00970]\], three studies investigated its correlation with DFS \[[@B35-cancers-11-00970],[@B87-cancers-11-00970],[@B93-cancers-11-00970]\], two with RFS \[[@B51-cancers-11-00970],[@B66-cancers-11-00970]\], and one study reported MFS \[[@B65-cancers-11-00970]\].

### 3.3.1. miR-222 Expression and OS {#sec3dot3dot1-cancers-11-00970}

We observed a high degree of heterogeneity among the 17 studies reporting OS and included in the meta-analysis (*I*^2^ = 77%, *p* \< 0.001). Despite this, the pooled results of miR-222 and OS provided evidence of significantly poorer prognosis in patients expressing higher levels of miR-222 (*N*~patients~ = 1782; HR: 1.90, 95% CI: 1.43--2.54, *p* \< 0.001; [Figure 3](#cancers-11-00970-f003){ref-type="fig"}A). There was no evidence of publication bias either from the funnel plot ([Figure 3](#cancers-11-00970-f003){ref-type="fig"}B) or from Egger's test (*p* = 0.299). Subgroup analyses were further performed to evaluate the robustness of the overall finding on the association between miR-222 expression and OS, based on the same seven categories used for miR-221; the data are presented in [Table 5](#cancers-11-00970-t005){ref-type="table"}. Statistically significant heterogeneity was detected in most of the subgroups except for studies performed in patients with liver cancer (*I*^2^ = 0%, *p* = 0.441), gastro-intestinal malignancies (*I*^2^ = 25%, *p* = 0.256), or NSCLC (*I*^2^ = 0%, *p* = 0.470) or studies with a NOS score of \<7 (*I*^2^ = 0%, *p* = 0.602). The results confirmed the significant association between high miR-222 expression and poor OS in all the subgroup analyses conducted, with the exception of studies including patients with urogenital cancer (HR: 1.22, 95% CI: 0.29--5.07, *p* = 0.781) and those conducted on FFPE tissues (HR: 1.22, 95% CI: 0.79--1.88, *p* = 0.360).

We also analyzed OS along with DSS; despite significant heterogeneity (*I*^2^ = 75%, *p* \< 0.001), high miR-221 expression was significantly associated with poor OS/DSS (pooled HR: 1.88, 95% CI: 1.46--2.42, *p* \< 0.001, [Supplementary Figure S4](#app1-cancers-11-00970){ref-type="app"}).

### 3.3.2. miR-222 Expression and Secondary Outcomes {#sec3dot3dot2-cancers-11-00970}

Despite a large degree of heterogeneity (*I*^2^ = 73%, *p* = 0.001), the results showed a significantly shorter PFS in patients with high expression of miR-222 (HR: 1.67, 95% CI: 1.10--2.51, *p* \< 0.015; [Supplementary Figure S5A](#app1-cancers-11-00970){ref-type="app"}). No evidence of publication bias or small-study effects was observed in either the funnel plot ([Supplementary Figure S5B](#app1-cancers-11-00970){ref-type="app"}) or in Egger's test (*p* = 0.914). When assessing the association of miR-222 with DFS pooled with RFS, high expression was associated with poor prognosis ([Table 4](#cancers-11-00970-t004){ref-type="table"}; [Supplementary Figure S6](#app1-cancers-11-00970){ref-type="app"}).

3.4. Sensitivity Analysis {#sec3dot4-cancers-11-00970}
-------------------------

For both miR-221 and 222, sensitivity analysis of the OS was performed to investigate the influence of each individual study on the pooled HRs. The analysis ([Supplementary Figure S7A,B](#app1-cancers-11-00970){ref-type="app"}, respectively) showed that the pooled results were not significantly altered by omitting any single data set. This result suggests that no single study significantly influenced the pooled HRs or the 95% CIs, highlighting that the pooled results of OS were robust.

4. Discussion {#sec4-cancers-11-00970}
=============

In the last two decades, compelling evidence has repeatedly demonstrated the key involvement of miRNAs in cancer \[[@B19-cancers-11-00970]\]. miRNAs minutely regulate a plethora of biological mechanisms at the post-transcriptional level, and an increasing number of studies have provided clues that aberrantly expressed miRNAs are involved in diagnosis and prognosis in numerous chronic diseases, including cancer \[[@B94-cancers-11-00970],[@B95-cancers-11-00970]\]. Specifically, miRNAs may have both oncogenic and tumor-suppressive roles in any step of cancerogenesis, depending on the cellular context and tumor type. Among the miRNAs frequently dysregulated in cancer, miR-221 and miR-222 are considered of great importance. Indeed, the miR-221/222 cluster acts as *onco-miR* in the majority of epithelial tumors \[[@B96-cancers-11-00970]\] while acting as *oncosuppressor-miR* in erythroleukemic cells \[[@B97-cancers-11-00970]\]. Recently, diverse reports have shown their prognostic importance as circulating molecules in plasma, blood, and other biological fluids (for a review on circulating molecules, see ref \[[@B98-cancers-11-00970]\]). Furthermore, one of the emerging relevant aspects is the contribution of miR-221 and miR-222 to the clinical outcome in cancer patients. To the best of our knowledge, to date, only two meta-analyses have assessed the association of miR-221 and miR-222 with the prognosis of patients with malignant tumors, respectively encompassing 1204 \[[@B44-cancers-11-00970]\] and 2693 \[[@B42-cancers-11-00970]\] patients. Results from both the meta-analyses agree on the association between miR-221/222 overexpression and poor OS and their possible translation into clinical practice. However, both meta-analyses were based on a limited number of studies. In particular, with regard to the primary outcome, few studies were published at the time of the first meta-analysis \[[@B40-cancers-11-00970]\], which included nine studies for miR-221 and four studies for miR-222. In the meta-analysis performed by Zhang and coworkers \[[@B42-cancers-11-00970]\], the authors pooled together miR-221 and miR-222; therefore, they suggested the development of biomarkers in cancer prognosis based on the cluster. However, some studies highlighted opposite results on survival outcomes between the two miRNAs; thus, a different prognostic role for miR-221 and miR-222 cannot be ruled out. In addition, Zhang et al. \[[@B42-cancers-11-00970]\]., combined different sample sources (i.e., tissue and blood), adding a degree of uncertainty to the conclusive result. In view of this evidence, we performed an updated meta-analysis to corroborate the previous conclusions and possibly uncover some novel findings on secondary outcomes, separately analyzing the prognostic roles of these two miRNAs. We identified 50 studies, published between 2009 and 2018, including a total of 6086 patients, covering 21 different tumor types, and representing the widest meta-analysis so far performed. The current study demonstrated that high expression of both miR-221 and miR-222 significantly predicted poor OS in cancer, confirming the findings of the two previous meta-analyses \[[@B42-cancers-11-00970],[@B44-cancers-11-00970]\]. Subgroup analysis revealed that the finding on miR-221 was not as robust as the one on miR-222. Indeed, high miR-222 expression was associated with poor OS, irrespectively of ethnicity, sample size, and quality score. On the contrary, miR-221 was a predictor of poor OS only in Asian (not in Caucasian) patients, in small cohorts of patients (\<100), and in high-quality studies (NOS ≥ 7). With regard to ethnicity, differences in the genetic background, dietary habits, and environmental exposure might in part explain the findings. However, the fact that significance is retained only in studies of small sample size makes the result unconvincing, and we cannot exclude the possibility that the significance of miR-221 is due to chance. Additionally, subgroup analysis based on tissue type did not reveal differences in the prognostic value of miR-221. On the contrary, high miR-222 expression was significantly associated with poor OS in fresh/frozen tissue but not in FFPE samples. The finding is consistent with the knowledge of a higher speed of RNA degradation in FFPE tissues than in the other two specimen types \[[@B99-cancers-11-00970]\]. With regard to secondary outcome, high expression of miR-222 was significantly associated with both worse PFS and worse DFS/RFS, whereas no association was observed with miR-221. Unfortunately, due to the limited number of studies investigating secondary outcomes, we could not perform a subgroup analysis to verify the robustness of the findings on miR-222. Despite this, the results on miR-222 are convincing, as they are consistent with OS. Overall, the findings have important clinical implications, as they may provide a rationale for the study and the development of a molecular sponge to regulate miR-222 expression \[[@B18-cancers-11-00970],[@B100-cancers-11-00970]\]. In this context, intensive research is currently ongoing to understand the role of miRNA sponges that could be used to control miRNA expression and therefore function for therapeutic purposes \[[@B101-cancers-11-00970],[@B102-cancers-11-00970]\].

Although the present meta-analysis provides evidence of the prognostic value of miR-222, several limitations should be highlighted. Primarily, although 50 relevant studies were identified, the number of studies for some cancer types was insufficient to be evaluated. Therefore, when analyzing OS, subgroup analysis was carried out by considering the anatomic site instead of the specific type of cancer. In this context, high miR-222 expression was associated with poor OS in all the anatomic sites of cancer with the exception of urogenital cancer. In view of this consideration, we should not underestimate the limitations associated with differences in patients' baseline characteristics, treatments received, duration of follow-up, and cancer stage as reported also for other miRNAs \[[@B81-cancers-11-00970],[@B85-cancers-11-00970],[@B89-cancers-11-00970],[@B103-cancers-11-00970],[@B104-cancers-11-00970],[@B105-cancers-11-00970]\]. Additional bias could arise from differences in the biological properties of the specific cancer types, particularly regarding the tumor microenvironment and the diversity of signals provided by the tumor cells. Further sources of micro statistical errors could be (i) the variety of cut-off values used to define miR-221/222 expression among studies; (ii) the calculation of HR and 95% CI from the survival curve in some studies; and (iii) the statistical methodology, i.e., the use of univariate in place of multivariate analysis in some investigations. Therefore, better-designed clinical studies are needed to gain new insights into the prognostic role of miR-222 in different human malignancies. In particular, to reduce the source of heterogeneity and make meta-analysis a powerful tool, we should also consider reaching an agreement on the clinical outcomes. Indeed, of the 23 studies investigating the prognostic role of miR-222, only 17 investigated OS, while the others explored the association with different secondary outcomes; these could not be analyzed together, reducing the number of studies eligible for the meta-analysis.

5. Conclusions {#sec5-cancers-11-00970}
==============

In conclusion, to the best of our knowledge, our study represents the widest meta-analysis so far performed on the prognostic value of miR-221 and miR-222. These findings should bring the attention of scientists to the importance of high miR-222 expression as a biomarker of poor prognosis in terms of both OS and secondary outcomes, including DFS and RFS. On the contrary, the results on miR-221 remain controversial. Despite the fact that no obvious publication bias was detected in the analysis, we cannot exclude that what we observed is a chance finding. Therefore, further large-scale prospective studies are warranted to validate the appropriateness of miR-222's poor prognosis prediction capability and to exclude the involvement of miR-221.
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![Forest (**A**) and Funnel (**B**) plots for the effect of miR-221 overexpression on overall survival. ES, effect size (i.e., hazard ratio); W, weight; Sig, statistical significance; N, total number of cancer patients included in the survival analysis.](cancers-11-00970-g002){#cancers-11-00970-f002}

![Forest (**A**) and Funnel (**B**) plots for the effect of miR-222 overexpression on overall survival. ES, effect size (i.e., hazard ratio); W, weight; Sig, statistical significance; N, total number of cancer patients included in the survival analysis.](cancers-11-00970-g003){#cancers-11-00970-f003}

cancers-11-00970-t001_Table 1

###### 

Main characteristics of studies evaluating the impact of higher expression of miR-221 or miR-222 on survival outcomes in cancer patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author \[Ref\] Year                                  Country              Sample Size (Pts Analyzed ^\#^)   Gender (M/F)                Age Median (Range) or Mean ± SD or Age Category   Cancer Type   Clinical Classification                                          Pre-Operative (Localized or Systemic) Treatment   Type of Specimen      NOS Score
  ---------------------------------------------------------- -------------------- --------------------------------- --------------------------- ------------------------------------------------- ------------- ---------------------------------------------------------------- ------------------------------------------------- --------------------- -----------
  Gramantieri et al. \[[@B91-cancers-11-00970]\] 2009        Italy                \(51\) 45                         40/11                       68 (49--82)                                       HCC           ES stage: G2--G4                                                 No                                                frozen tissue/FFPE    5

  Wang et al. \[[@B92-cancers-11-00970]\] 2010               China                85 (32 ALL)                       42/43                       43 (14--82)                                       ALL/AML       FAB classification; ALL: L1--L3, Tcell; AML: M0--M6, mast cell   NR                                                bone marrow           7

  Wong et al. \[[@B93-cancers-11-00970]\] 2010               China                99 (76)                           80/19                       57 (48--66.5)                                     HCC           T stage: T1--T3                                                  No (NAT in 3 pts)                                 frozen tissue         5

  Schaefer et al. \[[@B51-cancers-11-00970]\] 2010           Germany              76 (75)                           76/0                        63 (49--74)                                       PCa           Tumor stage: pT2--pT3                                            No                                                frozen tissue         8

  Spahn et al. \[[@B52-cancers-11-00970]\] 2010              Germany              92                                92/0                        67 (52--78)                                       PCa           Tumor stage: pT2--pT4                                            No                                                FFPE                  9

  Greither et al. \[[@B53-cancers-11-00970]\] 2010           Germany; UK          56 (52)                           34/22                       61.7 (34--80)                                     PC            NR                                                               NR                                                frozen tissue         6

  Yoon et al. \[[@B54-cancers-11-00970]\] 2011               Korea                115                               91/24                       51 (26--76)                                       HCC           TNM stage: I--III                                                No                                                FFPE                  7

  Delfino et al. \[[@B55-cancers-11-00970]\] 2011            USA                  253                               162/91                      55.7                                              GBM           WHO glioma grade 4                                               NS                                                NR                    6

  Alencar et al. \[[@B56-cancers-11-00970]\] 2011            USA; Canada; Spain   176                               NR                          59.5 (16--92)                                     Lymphoma      AAS: I--IV                                                       No                                                FFPE                  9

  Liu et al. \[[@B57-cancers-11-00970]\] 2012                China                92                                50/42                       59.3 ± 5.6                                        GC            TNM stage: I--III                                                No                                                frozen tissue         8

  Zhang et al. \[[@B58-cancers-11-00970]\] 2012              China                72 (36)                           NR                          NR                                                GM            Grade: I--IV                                                     NR                                                FFPE/frozen tissue    6

  Schultz et al. \[[@B59-cancers-11-00970]\] 2012            Denmark              328 (225)                         111/114                     64 (31--85)                                       PC            WHO stage: I--II                                                 NR                                                FFPE                  8

  Kang et al. \[[@B60-cancers-11-00970]\] 2012               Korea                92 (73)                           92/0                        64.7 (50--76)                                     PCa           TNM stage: T2--T3                                                NS                                                FFPE                  8

  Hanna et al. \[[@B61-cancers-11-00970]\] 2012              USA                  473                               NR                          NR                                                BC            NR                                                               NR                                                FFPE                  8

  Gimenes-Teixeira et al. \[[@B62-cancers-11-00970]\] 2013   Brazil               48 (42)                           39/9                        20.1 (1--66)                                      T-ALL         NR                                                               NR                                                Fresh/frozen tissue   7

  Lee et al. \[[@B63-cancers-11-00970]\] 2013                China                60 (36)                           38/22                       ≤60 y (*n* = 18);\                                PC            Stage: I--IV                                                     NR                                                frozen tissue         6
                                                                                                                                                \>60 y (*n* = 42)                                                                                                                                                                                        

  Yuan et al. \[[@B38-cancers-11-00970]\] 2013               USA                  108                               68/40                       \<65 y (*n* = 63)\                                CRC           T stage: T2--T4                                                  NR                                                frozen tissue         7
                                                                                                                                                ≥65 y (*n* = 45)                                                                                                                                                                                         

  Karakatsanis et al. \[[@B64-cancers-11-00970]\] 2013       Greece               81 (60 HCC)                       60/21                       ≤60 y (*n* = 21)\                                 HCC/ICC       T stage: T1--T4                                                  No                                                FFPE                  6
                                                                                                                                                \>60 y (*n* = 60)                                                                                                                                                                                        

  Kim et al. \[[@B65-cancers-11-00970]\] 2013                Korea                91 (MFS: 79; OS: 88)              57/34                       61 (25--80)                                       GC            Tumor stage: pT2--pT4                                            No                                                FFPE                  7

  Amankwah et al. \[[@B66-cancers-11-00970]\] 2013           USA                  65 (miR-221: 63; miR-222: 60)     65/0                        59.5 (46--75)                                     PCa           Stage: I--IV                                                     NR                                                FFPE                  7

  Mao et al. \[[@B67-cancers-11-00970]\] 2014                China                100                               59/41                       \<60 y (*n* = 34)\                                NSCLC         TNM stage: I--III                                                NR                                                frozen tissue         8
                                                                                                                                                ≥60 y (*n* = 66)                                                                                                                                                                                         

  Zhang et al. \[[@B68-cancers-11-00970]\] 2014              China                97                                51/46                       \<60 y (*n* = 59);\                               Bladder       T stage: Ta--T1 (*n* = 82);\                                     No                                                fresh/frozen tissue   8
                                                                                                                                                ≥60 y (*n* = 38)                                                ≥T2 (*n* = 15)                                                                                                                           

  Tao et al. \[[@B69-cancers-11-00970]\] 2014                China                90                                47/43                       \<70 y (*n* = 42);\                               CC            TNM stage: I--IV                                                 No                                                FFPE                  7
                                                                                                                                                ≥70 y (*n* = 46); unknown (*n* = 2)                                                                                                                                                                      

  Vergho et al. \[[@B70-cancers-11-00970]\] 2014             Germany              74 (37)                           48/26                       66.8                                              RCC           T stage: T1--T3; Tumor grade: G1--G4                             NR                                                FFPE                  8

  Gyöngyösi et al. \[[@B71-cancers-11-00970]\] 2014          Hungary              20                                16/4                        68 (52--82)                                       HCC           Advanced stage                                                   No                                                FFPE                  7

  Hur et al. \[[@B72-cancers-11-00970]\] 2015                USA                  393 (84)                          66/18                       64.6 ± 10.7 (*n* = 84)                            CRC           TNM stage: I--IV                                                 NR                                                frozen tissue         8

  Cai et al. \[[@B73-cancers-11-00970]\] 2015                China                182                               73/109                      52 ± 6.25                                         CC            TNM stage: I--III                                                No                                                FFPE                  8

  Li et al. \[[@B74-cancers-11-00970]\] 2015                 China                25                                14/11                       \<60 y (*n* = 13);\                               EHCC          Stage: I--IV                                                     No                                                frozen tissue         5
                                                                                                                                                ≥60 y (*n* = 12)                                                                                                                                                                                         

  Eissa et al. \[[@B75-cancers-11-00970]\] 2015              Egypt                78 (76)                           0/78                        52.28 ± 12                                        BC            Stage: I-III; grade: I--III                                      No                                                frozen tissue         9

  Goto et al. \[[@B76-cancers-11-00970]\] 2015               Japan                54 (52)                           54/0                        73.5 (58--88)                                     PCa           TNM stage: III--IV                                               NR                                                NR                    6

  García-Donas et al. \[[@B77-cancers-11-00970]\] 2016       Belgium              145 (74)                          90/48                       61.0 (35--82)                                     RCC           Metastatic                                                       immuno- or chemotherapy                           FFPE                  8

  Li et al. \[[@B78-cancers-11-00970]\] 2016                 China                45                                30/15                       \<50 y (*n* = 18);\                               GM            TNM stage: I--IV; T classification: T1--T4                       NR                                                fresh tissue          8
                                                                                                                                                ≥50 y (*n* = 27)                                                                                                                                                                                         

  Zhang et al. \[[@B79-cancers-11-00970]\] 2016              China                104                               58/46                       \<55 y (*n* = 44);\                               NSCLC         TNM stage: I--IV                                                 No                                                frozen tissue         7
                                                                                                                                                ≥55 y (*n* = 60)                                                                                                                                                                                         

  Fu et al. \[[@B39-cancers-11-00970]\] 2016                 China                74                                0/74                        \<50 y (*n* = 37);\                               OC            FIGO stage: I--IV                                                NR                                                FFPE                  8
                                                                                                                                                ≥50 y (*n* = 37)                                                                                                                                                                                         

  Chen et al. \[[@B80-cancers-11-00970]\] 2017               China                135                               76/59                       53.3 ± 9.1                                        HCC           Tumor stage: I--II                                               No                                                FFPE                  7

  Deng et al. \[[@B81-cancers-11-00970]\] 2017               China                125                               0/125                       51.6 (25--81)                                     BC            T stage: T1--T4                                                  No                                                FFPE                  6

  He et al. \[[@B82-cancers-11-00970]\] 2017                 China                31                                16/15                       2.9 (0.1--12)                                     NeuroB        Tumor stage IIb--IV                                              No                                                FFPE                  5

  Xue et al. \[[@B36-cancers-11-00970]\] 2017                China                165                               114/51                      \<60 y (*n* = 132)\                               GM            Tumor stage: I--IV                                               NR                                                frozen tissue         7
                                                                                                                                                ≥60 y (*n* = 33)                                                                                                                                                                                         

  Li et al. \[[@B83-cancers-11-00970]\] 2017                 China                40                                18/22                       \<60 y (*n* = 17);\                               HCC           NR                                                               No                                                frozen tissue         5
                                                                                                                                                \>60 y (*n* = 23)                                                                                                                                                                                        

  Li et al. \[[@B84-cancers-11-00970]\] 2017                 China                78                                52/26                       \<63 y (*n* = 38);\                               NSCLC         TNM stage: I--IV                                                 No                                                frozen tissue         8
                                                                                                                                                ≥63 y (*n* = 40)                                                                                                                                                                                         

  Xie et al. \[[@B85-cancers-11-00970]\] 2017                China                70                                38/32                       \<50 y (*n* = 29);\                               Liver         Tumor stage: I--IV                                               No                                                frozen tissue         8
                                                                                                                                                ≥50 y (*n* = 41)                                                                                                                                                                                         

  Xu et al. \[[@B86-cancers-11-00970]\] 2017                 China                178                               93/85                       \<60 y: *N* = 90;\                                NSCLC         Grade: Low: Ia--IIa; high: IIb--IIIa                             No                                                frozen tissue         6
                                                                                                                                                ≥60 y: *N* = 88                                                                                                                                                                                          

  Han et al. \[[@B87-cancers-11-00970]\] 2017                Korea                197                               0/197                       49 (27--85)                                       BC            T stage: T1--T3                                                  NR                                                FFPE                  8

  Wu et al. \[[@B88-cancers-11-00970]\] 2018                 China                107 (74)                          0/107                       \<50 y (*n* = 37);\                               OC            FIGO stage: I--IV                                                NR                                                FFPE                  6
                                                                                                                                                ≥50 y (*n* = 37); unknown (*n* = 74)                                                                                                                                                                     

  Gong et al. \[[@B89-cancers-11-00970]\] 2018               China                69                                38/31                       \<40 y (*n* = 51);\                               OsteoS        Tumor stage: II--III                                             NR                                                FFPE                  8
                                                                                                                                                ≥40 y (*n* = 18)                                                                                                                                                                                         

  Lei et al. \[[@B37-cancers-11-00970]\] 2018                China                230                               113/117                     \<55 y (*n* = 114);\                              NSCLC         TNM stage: I--IV                                                 No                                                FFPE                  7
                                                                                                                                                ≥55 y (*n* = 116)                                                                                                                                                                                        

  Liu et al. \[[@B40-cancers-11-00970]\] 2018                China                158                               95/63                       56.9 ± 7.4                                        CRC           TNM stage: I--IV                                                 No                                                FFPE                  9

  Tsikrika et al. \[[@B35-cancers-11-00970]\] 2018           Greece               182 (DSF/PFS: 101; OS: 57)        152/30                      70                                                Bladder       Tumor stage: pTa, pT1--pT4\                                      No                                                frozen/fresh tissue   9
                                                                                                                                                                                                                WHO grade: 1--3                                                                                                                          

  Iida et al. \[[@B90-cancers-11-00970]\] 2018               Japan                113 (101)                         49/52; unknown (*n* = 12)   68.0 ± 11.6                                       CRC           Tumor stage: I--II e IV                                          No                                                frozen tissue         7

  Chen et al. \[[@B41-cancers-11-00970]\] 2018               Taiwan               114                               68/46                       54 (38--65)                                       GBM           WHO glioma grade 4                                               NR                                                FFPE                  8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\# Patients analyzed. Abbreviations: AAS, Ann Arbor System of staging; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CC, colon cancer; CRC, colorectal cancer; DFS, disease-free survival; EHCC, extrahepatic cholangiocarcinoma; ES; Edmondson and Steiner's criteria; FFPE, formalin-fixed, paraffin-embedded tissue; FIGO: International Federation of Obstetricians and Gynecologists; GC, gastric cancer; GBM, glioblastoma; GM, glioma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; MFS, metastasis-free survival; NA, not applicable; NAT, neoadjuvant therapy; NeuroB: Neuroblastoma; NOS, Newcastle--Ottawa Scale; NR, not reported; NS, not specified; NSCLC, non-small cell lung cancer; OC, ovarian cancer; OS, overall survival; OsteoS: Osteosarcoma; PC, pancreatic cancer; PCa, prostate cancer; PFS, progression-free survival; RCC, renal cell carcinoma; SD, standard deviation; T-ALL, T-cell acute lymphoblastic leukemia; TNM, tumor nodes and metastases staging system.

cancers-11-00970-t002_Table 2

###### 

Characteristics and prognostic information extracted from the studies included in the systematic review.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author \[Ref\] Year                                  miRNA Analyzed and Clinical Outcome Extracted                     Detection Method   Cut-Off Value               Clinical Outcome: HR (95% CI)
  ---------------------------------------------------------- ----------------------------------------------------------------- ------------------ --------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Gramantieri et al. \[[@B91-cancers-11-00970]\] 2009        miR-221: TTR ^u^/CSS ^u^                                          qRT-PCR            median                      TTR: 1.73 (1.15--2.60) \*; CSS: 1.27 (0.64--2.52) \*

  Wang et al. \[[@B92-cancers-11-00970]\] 2010               miR-221: OS ^m^                                                   qRT-PCR            median                      OS: 0.54 (0.30--0.97)

  Wong et al. \[[@B93-cancers-11-00970]\] 2010               miR-222 OS ^u^/DFS ^u^                                            qRT-PCR            fold change ≥ 2             OS: 3.12 (1.42--5.56); DFS: 2.21 (1.19--3.83)

  Schaefer et al. \[[@B51-cancers-11-00970]\] 2010           miR-221: RFS ^m^;miR-222: RFS ^m^                                 qRT-PCR            median                      RFS: 0.50 (0.01--39.1); RFS: 5.04 (0.03--9.40)

  Spahn et al. \[[@B52-cancers-11-00970]\] 2010              miR-221: RFS ^m^                                                  qRT-PCR            median                      RFS: 0.53 (0.29--0.95)

  Greither et al. \[[@B53-cancers-11-00970]\] 2010           miR-222: OS ^m^                                                   qRT-PCR            median                      OS: 2.05 (1.05--4.00)

  Yoon et al. \[[@B54-cancers-11-00970]\] 2011               miR-221: TTLR ^m^                                                 qRT-PCR            mean                        TTLR: 3.07 (1.56--6.07)

  Delfino et al. \[[@B55-cancers-11-00970]\] 2011            miR-221: OS ^m^\                                                  Microarray         NR                          OS: 0.55 (0.34--0.88); OS: 2.14 (1.51--3.03); PFS: 1.44 (1.11--1.86)
                                                             miR-222: OS ^m^/PFS ^m^                                                                                          

  Alencar et al. \[[@B56-cancers-11-00970]\] 2011            miR-222: PFS ^m^                                                  qRT-PCR            median                      PFS: 2.26 (1.24--4.14)

  Liu et al. \[[@B57-cancers-11-00970]\] 2012                miR-221: OS ^m^                                                   qRT-PCR            mean                        OS: 2.32 (1.11--4.85)

  Zhang et al. \[[@B58-cancers-11-00970]\] 2012              miR-221: OS ^u^\                                                  IHC                final score ≤ 3             OS: 2.53 (1.24--5.18) \*; OS: 2.97 (1.19--7.74) \*
                                                             miR-222: OS ^u^                                                                                                  

  Schultz et al. \[[@B59-cancers-11-00970]\] 2012            miR-222: OS ^m^                                                   microarray         10th percentile             OS: 1.39 (1.06--1.84)

  Kang et al. \[[@B60-cancers-11-00970]\] 2012               miR-221: RFS ^u^                                                  qRT-PCR            median                      RFS: 0.36 (0.17--1.90)

  Hanna et al. \[[@B61-cancers-11-00970]\] 2012              miR-221: CSS ^m^                                                  qRT-PCR            75th percentile             CSS: 0.70 (0.51--0.97)

  Gimenes-Teixeira et al. \[[@B62-cancers-11-00970]\] 2013   miR-221: OS ^m^/DFS ^m^                                           qRT-PCR            median                      OS: 2.31 (0.92--5.81); DFS: 1.54 (0.57--4.17)

  Lee et al. \[[@B63-cancers-11-00970]\] 2013                miR-222: OS ^m^                                                   qRT-PCR            median                      OS: 5.16 (1.16--22.91)

  Yuan et al. \[[@B38-cancers-11-00970]\] 2013               miR-221: OS ^m^/DFS ^m^                                           qRT-PCR            NR                          OS: 0.18 (0.09--0.16); DFS: 0.04 (0.01--0.16)

  Karakatsanis et al. \[[@B64-cancers-11-00970]\] 2013       miR-221: OS ^m^                                                   qRT-PCR            mean                        OS: 1.79 (1.24--2.58)

  Kim et al. \[[@B65-cancers-11-00970]\] 2013                miR-221: MFS ^u^\                                                 qRT-PCR            fold change ≥ 3             MFS: 1.72 (1.03--2.89) \*; OS: 1.50 (0.70--2.90); MFS: 1.92 (1.05--3.50) \*
                                                             miR-222 OS ^m^/MFS ^u^                                                                                           

  Amankwah et al. \[[@B66-cancers-11-00970]\] 2013           miR-221: RFS ^m^\                                                 qRT-PCR            median                      RFS: 1.79 (0.67--4.76); RFS: 2.56 (0.87--7.14)
                                                             miR-222: RFS ^m^                                                                                                 

  Mao et al. \[[@B67-cancers-11-00970]\] 2014                miR-222: OS ^m^                                                   qRT-PCR            median                      OS: 3.31 (1.97--5.58)

  Zhang et al. \[[@B68-cancers-11-00970]\] 2014              miR-222: OS ^m^                                                   qRT-PCR            median                      OS: 6.17 (2.33--10.39)

  Tao et al. \[[@B69-cancers-11-00970]\] 2014                miR-221: OS ^m^                                                   qRT-PCR            median                      OS: 2.04 (1.09--3.81)

  Vergho et al. \[[@B70-cancers-11-00970]\] 2014             miR-221: CSS ^m^                                                  qRT-PCR            1.84 of ROC curve           CSS: 0.47 (0.22--1.00)

  Gyöngyösi et al. \[[@B71-cancers-11-00970]\] 2014          miR-221: OS ^u^/PFS ^u^\                                          qRT-PCR            median                      OS: 1.92 (0.61--6.10); PFS: 1.32 (0.47--3.66); OS: 2.04 (0.64--6.46); PFS: 1.43 (0.51--3.99)
                                                             miR-222: OS ^u^/PFS ^u^                                                                                          

  Hur et al. \[[@B72-cancers-11-00970]\] 2015                miR-221: OS ^m^                                                   Microarray         1.68 of ROC curve           OS: 1.64 (0.73--3.71)

  Cai et al. \[[@B73-cancers-11-00970]\] 2015                miR-221: OS ^m^                                                   qRT-PCR            median                      OS: 2.39 (1.21--4.91)

  Li et al. \[[@B74-cancers-11-00970]\] 2015                 miR-221: DFS ^u^                                                  qRT-PCR            median                      DFS: 2.19 (1.07--4.47) \*

  Eissa et al. \[[@B75-cancers-11-00970]\] 2015              miR-221: RFS ^m^                                                  qRT-PCR            1.03 of ROC curve           RFS: 14.84 (1.89--116.25)

  Goto et al. \[[@B76-cancers-11-00970]\] 2015               miR-221: PFS ^u^\                                                 qRT-PCR            NR                          PFS: 0.69 (0.42--1.14) \*; PFS: 0.21 (0.07--0.64)
                                                             miR-222: PFS ^m^                                                                                                 

  García-Donas et al. \[[@B77-cancers-11-00970]\] 2016       miR-221: DSS ^m^/PFS ^m^\                                         NGS and qRT-PCR    median                      DSS: 1.71 (1.35--2.16); PFS: 2.25 (1.67--3.02); DSS: 1.77 (1.41--2.22); PFS: 2.02 (1.51--2.71)
                                                             miR-222: DSS ^m^/PFS ^m^                                                                                         

  Li et al. \[[@B78-cancers-11-00970]\] 2016                 miR-221: OS ^u^\                                                  qRT-PCR            mean                        OS: 2.18 (1.02--4.65); OS: 2.13 (1.01--4.48)
                                                             miR-222: OS ^u^                                                                                                  

  Zhang et al. \[[@B79-cancers-11-00970]\] 2016              miR-221: OS ^m^                                                   qRT-PCR            mean                        OS: 1.87 (1.27--2.77)

  Fu et al. \[[@B39-cancers-11-00970]\] 2016                 miR-222: OS ^m^                                                   qRT-PCR            median                      OS: 0.35 (0.16--0.73)

  Chen et al. \[[@B80-cancers-11-00970]\] 2017               miR-221: OS ^m^/DFS ^m^                                           qRT-PCR            median                      OS: 2.97 (1.63--5.41); DFS: 2.85 (1.56--5.18)

  Deng et al. \[[@B81-cancers-11-00970]\] 2017               miR-221: DFS ^m^                                                  qRT-PCR            median                      DFS: 0.48 (0.26--0.88)

  He et al. \[[@B82-cancers-11-00970]\] 2017                 miR-221: OS ^u^                                                   qRT-PCR            mean                        OS: 1.65 (1.02--2.68)

  Xue et al. \[[@B36-cancers-11-00970]\] 2017                miR-221: OS ^u^                                                   qRT-PCR            median                      OS: 1.66 (1.13--2.49)

  Li et al. \[[@B83-cancers-11-00970]\] 2017                 miR-221: OS ^u^                                                   qRT-PCR            NR                          OS: 1.87 (0.47--7.43) \*

  Li et al. \[[@B84-cancers-11-00970]\] 2017                 miR-221: OS ^m^                                                   qRT-PCR            median                      OS: 3.01 (0.53--17.07)

  Xie et al. \[[@B85-cancers-11-00970]\] 2017                miR-221: OS ^m^                                                   qRT-PCR            NR                          OS: 1.74 (1.00--3.77)

  Xu et al. \[[@B86-cancers-11-00970]\] 2017                 miR-222: OS ^m^/PFS ^u^                                           qRT-PCR            mean                        OS: 3.23 (2.12--5.47); PFS: 2.62 (1.56--4.39) \*

  Han et al. \[[@B87-cancers-11-00970]\] 2017                miR-222: DFS ^m^                                                  qRT-PCR            median                      DFS: 5.67 (1.08--29.76)

  Wu et al. \[[@B88-cancers-11-00970]\] 2018                 miR-221: OS ^u^                                                   qRT-PCR            median                      OS: 0.39 (0.20--0.80)

  Gong et al. \[[@B89-cancers-11-00970]\] 2018               miR-221: OS ^m^                                                   qRT-PCR            median                      OS: 3.24 (1.17--9.01)

  Lei et al. \[[@B37-cancers-11-00970]\] 2018                miR-222: OS ^m^                                                   IHC                final score ≥ 5             OS: 2.23 (1.35--3.67)

  Liu et al. \[[@B40-cancers-11-00970]\] 2018                miR-221: OS ^m^/LRR ^m^/DMR ^m^                                   qRT-PCR            Youden index of ROC curve   OS: 1.01 (0.57--1.77); DMR: 1.21 (0.66--2.20); LRR: 1.17 (0.65--2.11)

  Tsikrika et al. \[[@B35-cancers-11-00970]\] 2018           miR-221: OS ^u^/DFS ^u^/PFS ^u^ miR-222: OS ^u^/DFS ^m^/PFS ^m^   qRT-PCR            30th percentile             OS: 1.69 (0.41--6.84) \*; DFS: 0.71 (0.38--1.33); PFS: 1.37 (0.54--3.62); OS: 0.87 (0.57--1.33) \*; DFS: 2.59 (1.15--5.83); PFS: 8.98 (1.10--73.54)

  Iida et al. \[[@B90-cancers-11-00970]\] 2018               miR-221: OS ^u^\                                                  qRT-PCR            median                      OS: 1.70 (0.87--3.32); OS: 1.51 (0.78--2.94)
                                                             miR-222: OS ^u^                                                                                                  

  Chen et al. \[[@B41-cancers-11-00970]\] 2018               miR-221: OS ^m^\                                                  qRT-PCR            fold change \> 1            OS: 2.11 (1.12--3.97); OS: 1.01 (0.64--1.58)
                                                             miR-222: OS ^m^                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^m^ Multivariate; ^u^ univariate; \* data extracted from the Kaplan--Meier curve. Abbreviations: CSS, cancer-specific survival; DFS, disease-free survival; DMR, distant metastasis rate; DSS, disease-specific survival; HR, hazard ratio; IHC, immunohistochemistry; LRR, local recurrence rate; MFS, metastasis-free survival; NGS, next-generation sequencing; NR, not reported; OS, overall survival; PFS, progression-free survival; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RFS, recurrence-free survival; ROC, receiver operating characteristic; TTLR, time to local recurrence; TTR, time to recurrence.

cancers-11-00970-t003_Table 3

###### 

Summary of random effect meta-analyses for the association between miR-221 overexpression and overall survival of cancer patients.

  Study Groups                Studies Included   Test of Association   Test of Heterogeneity        
  --------------------------- ------------------ --------------------- ----------------------- ---- ---------
  **All studies**             25                 1.48 (1.14--1.93)     0.003                   75   \<0.001
  **Ethnicity**                                                                                     
  Asian                       18                 1.67 (1.30--2.14)     \<0.001                 62   \<0.001
  Mostly Caucasian            5                  1.30 (0.69--2.44)     0.410                   75   0.003
  Mixed                       2                  0.64 (0.05--7.72)     0.723                   94   \<0.001
  **Type of cancer**                                                                                
  Liver                       5                  1.98 (1.51--2.60)     \<0.001                 0    0.698
  Gastro-intestinal           7                  1.29 (0.68--2.43)     0.434                   83   \<0.001
  Neurological                6                  1.56 (0.98--2.48)     0.062                   77   \<0.001
  Urogenital                  2                  0.72 (0.18--2.90)     0.638                   70   0.069
  NSCLC                       2                  1.92 (1.31--2.81)     0.001                   0    0.602
  Other                       3                  1.51 (0.45--5.01)     0.504                   84   0.002
  **No pre-treatment ^\#^**   14                 1.84 (1.56--2.17)     \<0.001                 0    0.813
  **Sample detected**                                                                               
  Fresh/frozen tissue         12                 1.54 (1.05--2.28)     0.028                   70   \<0.001
  FFPE                        10                 1.68 (1.20--2.36)     0.003                   66   0.002
  **Sample size \***                                                                                
  ≥100                        9                  1.27 (0.78--2.08)     0.332                   86   \<0.001
  \<100                       16                 1.62 (1.21--2.18)     0.001                   58   0.002
  **Survival analysis**                                                                             
  Univariate                  9                  1.54 (1.07--2.21)     0.020                   55   0.024
  Multivariate                16                 1.46 (1.02--2.09)     0.039                   81   \<0.001
  **NOS score**                                                                                     
  ≥7                          19                 1.61 (1.20--2.16)     0.002                   71   \<0.001
  \<7                         6                  1.17 (0.65--2.11)     0.604                   84   \<0.001

\* Number of cancer patients; ^\#^ Patients without pre-operative anticancer treatment; FFPE, formalin-fixed, paraffin-embedded tissue; HR, hazard ratio; NOS, Newcastle--Ottawa Scale; NSCLC, non-small cell lung cancer.

cancers-11-00970-t004_Table 4

###### 

Summary of meta-analyses for the association between high miR-221/222 expression and survival outcomes in cancer patients.

  Survival Outcome   Studies Included   Test of Association   Test of Heterogeneity   Egger's *p*-Value        
  ------------------ ------------------ --------------------- ----------------------- ------------------- ---- -------
  **miR-221**                                                                                                  
    CSS              3                  0.75 (0.48--1.17)     0.205                   0.148               48   0.913
    CSS/DSS          4                  0.95 (052--1.76)      0.878                   \<0.001             88   0.448
    DFS              6                  0.79 (0.31--1.98)     0.614                   \<0.001             89   0.338
    RFS              5                  1.09 (0.37--3.17)     0.881                   0.007               71   0.443
    PFS              4                  1.31 (0.65--2.63)     0.452                   0.001               82   0.504
  **miR-222**                                                                                                  
    PFS              7                  1.67 (1.10--2.51)     0.015                   0.001               73   0.914
    DFS              3                  2.50 (1.58--3.94)     \<0.001                 0.573               0    0.053
    DFS/RFS          5                  2.52 (1.66--3.82)     \<0.001                 0.573               0    0.143

Abbreviations: CSS, cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.

cancers-11-00970-t005_Table 5

###### 

Summary of random effect meta-analyses for the association between miR-222 overexpression and OS in cancer patients.

  Study Groups                Studies Included   Test of Association   Test of Heterogeneity        
  --------------------------- ------------------ --------------------- ----------------------- ---- ---------
  **All studies**             17                 1.90 (1.43--2.54)     \<0.001                 77   \<0.001
  **Ethnicity**                                                                                     
  Asian                       12                 2.11 (1.40--3.17)     \<0.001                 79   \<0.001
  Mostly Caucasian            5                  1.52 (1.07--2.18)     0.021                   66   0.019
  **Type of cancer**                                                                                
  Liver                       2                  2.80 (1.55--5.04)     0.001                   0    0.441
  Gastro-intestinal           5                  1.52 (1.22--1.90)     \<0.001                 25   0.256
  Neurological                4                  1.80 (1.12--2.90)     0.015                   66   0.033
  Urogenital                  3                  1.22 (0.29--5.07)     0.781                   93   \<0.001
  NSCLC                       3                  2.88 (2.16--3.83)     \<0.001                 0    0.470
  **No pre-treatment ^\#^**   8                  2.16 (1.37--3.42)     0.001                   77   \<0.001
  **Sample detected**                                                                               
  Fresh/frozen tissue         9                  2.48 (1.60--3.85)     \<0.001                 77   \<0.001
  FFPE                        6                  1.22 (0.79--1.88)     0.360                   73   0.002
  Sample size \*                                                                                    
  ≥100                        7                  1.93 (1.40--2.66)     \<0.001                 74   0.001
  \<100                       5                  1.92(1.13--3.28)      0.016                   81   \<0.001
  **Survival analysis**                                                                             
  Univariate                  6                  1.82 (1.12--2.97)     0.016                   64   0.015
  Multivariate                11                 1.94 (1.34--2.80)     \<0.001                 81   \<0.001
  **NOS score**                                                                                     
  ≥7                          11                 1.58 (1.09--2.30)     0.016                   80   \<0.001
  \<7                         6                  2.56 (2.03--3.22)     \<0.001                 0    0.602

\* Number of cancer patients; ^\#^ Patients without pre-operative anticancer treatment; **FFPE**, formalin-fixed, paraffin-embedded tissue; **HR**, hazard ratio; **NOS**, Newcastle--Ottawa Scale; **NSCLC**, non-small cell lung cancer.
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